[Skip to Content]

Quiz

Oncology

Prostate Cancer CME Series: Treatment Across the Prostate Cancer ContinuumSpecialists' Track

Learning Objectives
1. Identify prostate cancer patients who should be offered genetic testing
2. Recognize the difference between germline and somatic genetic testing and main categories to test each and their strengths and limitations
3. Describe the capabilities of PSMA-PET imaging for prostate cancer
4. Discuss PSMA targeted PET interpretation

1.5 Credits CME

Stanford Medicine

Activity Information and Disclosures

Published Online: August 25, 2022 Video 1 hr 27 min 4 sec

Watch Take Quiz Resources

Internet Enduring Material sponsored and presented by the Center for Continuing Medical Education at the Stanford School of Medicine. This is a recorded presentation of Prostate Cancer CME Series: Treatment Across the Prostate Cancer Continuum for Specialists held on Monday, June 27, 2022. The goal of the series is to enhance understanding of increasingly complex treatment options and close knowledge gaps in earlier stages of prostate cancer. This webinar is targeted towards medical oncologists, urologists and radiation oncologists. Hear from experts: Ali Khakhi, MD, Andrei Iagaru, MD, Sumit Shah, MD and Sandy Srinivas, MD. Topics will include: germline and somatic testing, risk stratification for localized prostate cancer and answer questions on when to do prostatectomy vs radiation.

Take Quiz

Resources

References: Prostate Cancer CME Series – Specialists' Track

Sign in to take quiz and track your certificates

Video Information

All Rights Reserved. The content of this activity is protected by U.S. and International copyright laws. Reproduction and distribution of its content without written permission of its creator(s) is prohibited.

Financial Support Disclosure Statement: Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity, except those listed in the table below. All of the relevant financial relationships listed for these individuals have been mitigated.

Sumit Anil Shah, MD

Stanford

Co-Course Director

Advisor-Natera|Grant or research support-Genentech, Inc.

Ali R Khaki, MD

Clinical Assistant Professor

Stanford Health Care (SHC)

Co-Course Director, Faculty

Stocks or stock options, excluding diversified mutual funds-Merck and Company, Inc. (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Sanofi-Aventis (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Doximity (Relationship has ended)

Hilary Petersmeyer Bagshaw, MD

Stanford University

Faculty

Nothing to disclose

Benjamin Inbeh Chung, MD

Stanford Health Care (SHC)

Faculty

Consulting Fee-Johnson and Johnson|Honoraria-Intuitive Surgical

Andrei Horia Iagaru, MD

Professor

Stanford University

Faculty

Advisor-GE Healthcare Bio-Sciences|Advisor-Novartis AG|Advisor-Lantheus|Advisor-Clarity Pharmaceuticals|Advisor-ITM

Sandhya Srinivas, MD

Stanford Health Care (SHC)

Faculty

Advisor-Bayer Corporation|Advisor-Johnson and Johnson|Advisor-Merck and Company, Inc.|Advisor-Novartis AG

Laura Ruffo, NP

Stanford Health Care (SHC)

Planner

Nothing to disclose

Ruth Adewuya, MD, CHCP

Managing Director, CME

Stanford University School of Medicine

Planner, Reviewer

Nothing to disclose

Accreditation
In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation
Stanford Medicine designates this Enduring Material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.